How many Pumitamig clinical trials are there?

17 Pumitamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 15 are actively recruiting participants.

Are Pumitamig clinical trials recruiting in 2026?

Yes — 15 Pumitamig trials are actively recruiting in 2026, with 190 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Pumitamig being studied for?

Pumitamig is being studied for Advanced Solid Tumor, Non-small Cell Lung Cancer, Breast Neoplasms, Extensive-stage Small-cell Lung Cancer, Hepatocellular Carcinoma (HCC) and 11 more. The trials are grouped by indication on this page.

What phase is Pumitamig in?

Pumitamig clinical trials span 4 Phase 3, 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Pumitamig clinical trials?

The lead sponsor across the most Pumitamig trials is BioNTech SE, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Pumitamig Clinical Trials (2026): 17 Studies for Advanced Solid Tumor & Non-small Cell Lung Cancer

Creator: Hipa.ai Research
Published: 2026-06-02T17:12:23.333Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 16, 2026.

17 Pumitamig clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 15 indications (including Advanced Solid Tumor & Non-small Cell Lung Cancer) and 8,459 total planned enrollment. 4 Phase 3 Pumitamig trials and 4 Phase 2 are listed. 17 Pumitamig clinical trials are actively recruiting at 190 U.S. sites across 38 states. Most recent activity: NCT07221357 (Mar 2034).

Where to Participate: All Pumitamig Trial Sites in the U.S. (190 sites across 38 states)

Every actively recruiting Pumitamigtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	The University of Alabama at Birmingham Hospital	Birmingham35249	NCT06841055	Map
AL	University of Alabama at Birmingham	Birmingham35294	NCT06618287	Map
AL	Southern Cancer Center Pc	Daphne36526	NCT07361497	Map
AL	Southern Cancer Center Pc	Daphne36526	NCT07361510	Map
AK	Alaska Oncology and Hematology, LLC	Anchorage99508	NCT06712316	Map
AZ	ACRC Arizona Clinical Research Center	Tucson85715	NCT06712355	Map
AR	Highlands Oncology Group	Springdale72762	NCT07173751	Map
CA	John Muir Clinical Research Center	Concord94520	NCT06712316	Map
CA	Orange Coast Memorial Medical Center	Fountain Valley92708	NCT07361510	Map
CA	University Of California - San Diego Moores Cancer Center	La Jolla92093	NCT06712316	Map
CA	University Of California - San Diego Moores Cancer Center	La Jolla92037	NCT07173751	Map
CA	Cedar Sinai - Samuel Oschin Cancer Center	Los Angeles90048	NCT07173751	Map
CA	USC/Norris Comprehensive Cancer Center	Los Angeles90033	NCT07221357	Map
CA	University of California, Irvine (UCI) Health - UC Irvine Medical Center	Orange92868	NCT07221149	Map
CA	University of California, Irvine (UCI) Health - UC Irvine Medical Center	Orange92868	NCT07221357	Map
CA	Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center	Palo Alto94304-2201	NCT07173751	Map
CT	Hartford Healthcare	Hartford06102	NCT07070232	Map
CT	Yale University	New Haven06511	NCT07070232	Map
DE	Medical Oncology Hematology Consultants, PA	Newark19713	NCT07361497	Map
DC	Sibley Memorial Hospital	Washington D.C.20016	NCT07293351	Map
FL	Florida Cancer Specialists - East	Cape Coral33990	NCT07221357	Map
FL	Clermont Oncology Center	Clermont34711	NCT06712316	Map
FL	Clermont Oncology Center	Clermont34711	NCT07361510	Map
FL	Advanced Research	Coral Springs33321	NCT07361510	Map
FL	Florida Cancer Specialists - South	Fort Myers33901	NCT07221149	Map
FL	BRP- Hialeah Hospital	Hialeah33013	NCT07361510	Map
FL	University of Miami Hospital and Clinics, Sylvester Cancer Center	Miami33136	NCT06618287	Map
FL	Mid Florida Cancer Centers	Orange City32763	NCT06712316	Map
FL	Cancer Care Centers of Brevard, Inc	Palm Bay32901	NCT06712355	Map
FL	Sacred Heart Medical Oncology Group	Pensacola32504	NCT07173751	Map
FL	Florida Cancer Specialists	Sarasota34232	NCT07070232	Map
FL	Florida Cancer Specialists - North	St. Petersburg33701	NCT07221149	Map
FL	Florida Cancer Specialists - North	St. Petersburg33705	NCT07221357	Map
FL	Cleveland Clinic Florida - Martin North Hospital	Stuart34994	NCT06712316	Map
FL	H. Lee Moffit Cancer center and research institute	Tampa33612	NCT06712316	Map
FL	Moffitt Cancer Center	Tampa33612	NCT06841055	Map
FL	Moffitt Cancer Center	Tampa33612-9497	NCT07070232	Map
FL	Moffitt Cancer Center	Tampa33612	NCT07221357	Map
FL	Cleveland Clinic Weston Hospital	Weston33331	NCT06712316	Map
GA	University Cancer & Blood Center, LLC	Athens30607	NCT07361510	Map
GA	Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital	Marietta30060	NCT07221357	Map
GA	Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital	Marietta30060	NCT07361510	Map
IL	Cancer Care Specialists	Decatur62526	NCT07173751	Map
IL	Illinois Cancer Specialists	Niles60714	NCT06712355	Map
IL	Cancer Care Specialists of Illinois	O'Fallon62269	NCT07173751	Map
IL	Illinois Cancer Care	Peoria61615	NCT07361497	Map
IL	Carle Foundation Hospital d/b/a Carle Cancer Center	Urbana61801	NCT07173751	Map
IN	Northwest Cancer Centers, P.C.	Dyer46311	NCT07361510	Map
IN	Fort Wayne Medical Oncology and Hematology	Fort Wayne46804	NCT07361497	Map
IN	Fort Wayne Medical Oncology and Hematology, Inc	Fort Wayne46804	NCT06712355	Map
IN	Fort Wayne Medical Oncology and Hematology, Inc.	Fort Wayne46845	NCT06712316	Map
IA	McFarland Clinic	Ames50010	NCT06712355	Map
IA	Helen G. Nassif Community Cancer Center	Cedar Rapids52403	NCT06712355	Map
IA	Physicians Clinic of Iowa	Cedar Rapids52401-2112	NCT06712316	Map
IA	Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics	Iowa City52242	NCT06712316	Map
KY	Baptist Health Hardin	Elizabethtown42701	NCT06712316	Map
KY	Baptist Health Hardin	Elizabethtown42701	NCT06841055	Map
KY	Baptist Health Hardin Cancer Center	Elizabethtown42701	NCT06712355	Map
KY	University Medical Center, Inc. DBA University of Louisville Hospital/James Graham Brown Cancer Center	Louisville40202	NCT07173751	Map
ME	New England Cancer Specialists	Westbrook04092	NCT07173751	Map
MD	Johns Hopkins Hospital	Baltimore21287	NCT07293351	Map
MD	Saint Agnes Hospital, Clinical Research Center	Baltimore21229	NCT07173751	Map
MD	Frederick Health Hospital- James M Stockman Cancer Institute	Frederick21704	NCT06712316	Map
MD	Frederick Health Hospital- James M Stockman Cancer Institute	Frederick21704	NCT06712355	Map
MD	Maryland Oncology Hematology - Silver Spring	Silver Spring20904	NCT07221357	Map
MA	Massachusetts General Hospital	Boston02215	NCT07070232	Map
MA	Beth Israel Lahey Health - Lahey Hospital & Medical Center (LHMC), Lahey Clinic Medical Center	Burlington01805	NCT06712355	Map
MA	Lahey Hospital & Medical Center	Burlington01805	NCT07173751	Map
MI	Karmanos Cancer Center	Detroit48201	NCT07173751	Map
MI	START Midwest, LLC	Grand Rapids49546	NCT07070232	Map
MI	Profound Research LLC at Michigan Hematology and Oncology Consultants	Royal Oak48073	NCT07173751	Map
MN	Minnesota Oncology	Maple Grove55369	NCT07221357	Map
MN	Minnesota Oncology Hematology	Maple Grove55369	NCT07361497	Map
MS	Baptist Cancer Center	Southaven38671	NCT06712355	Map
MO	Missouri Cancer Associates	Columbia65201	NCT06712316	Map
MO	Missouri Cancer Associates	Columbia65201	NCT07221149	Map
MO	Missouri Cancer Associates	Columbia65201	NCT07361497	Map
MO	Missouri Cancer Associates	Columbia65201	NCT07361510	Map
MO	SSM Health Cancer Care - St. Clare	Fenton63026	NCT06712316	Map
MO	Saint Luke's Hospital of Kansas City	Kansas City64111	NCT07173751	Map
MO	Washington University School of Medicine	St Louis63110	NCT06712355	Map
MO	Washington University School of Medicine	St Louis63110	NCT07293351	Map
MO	Washington University School OF Medicine-Siteman Cancer Center	St Louis63110	NCT07221357	Map
NE	Oncology Hematology West, PC dba Nebraska Cancer Specialist	Grand Island68803	NCT07173751	Map
NE	Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC)	Hastings68901-4470	NCT06712316	Map
NE	Nebraska Hematology-Oncology (NHO)	Lincoln68506	NCT06712355	Map
NE	Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha68310	NCT07173751	Map
NE	University Of Nebraska Medical Center	Omaha68198	NCT07221357	Map
NJ	Astera Cancer Care	East Brunswick08816	NCT06712316	Map
NJ	Summit Medical Group PA	Florham Park07932	NCT06712316	Map
NJ	Summit Medical Group PA	Florham Park07932	NCT07173751	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT06618287	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601-2191	NCT07291076	Map
NJ	The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion	Paramus07652	NCT06712316	Map
NY	Northwell Health/ RJ Zuckerberg Cancer Center	Lake Success11042	NCT07221149	Map
NY	Northwell Health/ RJ Zuckerberg Cancer Center	Lake Success11042	NCT07221357	Map
NY	Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center	New York10065	NCT06712355	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07221149	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT07361497	Map
NY	Memorial Sloan Kettering Hospital	New York10065	NCT07070232	Map
NY	NYU Langone - NYU Grossman School of Medicine	New York10016	NCT06841055	Map
NY	Rochester General Hospital Lipson Cancer Institute	Rochester14621	NCT07173751	Map
NY	Stony Brook University Medical Center	Stony Brook11794	NCT07173751	Map
NY	Suny-Stony Brook University Cancer Center	Stony Brook11794-9446	NCT06712316	Map
NY	Montefiore Medical Center	The Bronx10461	NCT07173751	Map
NY	White Plains Hospital	White Plains10601	NCT06712316	Map
NY	White Plains Hospital	White Plains10601	NCT06712355	Map
NC	Fletcher Hospital, Inc. dba AdventHealth Hendersonville	Hendersonville28792	NCT06712316	Map
ND	Sanford Fargo Medical Center	Fargo58102	NCT07221357	Map
OH	Cleveland Clinic - Akron General Hematology & Oncology	Akron44302	NCT06712355	Map
OH	Cleveland Clinic Mercy Hospital Cancer Center	Canton44708	NCT06712355	Map
OH	Gabrail Cancer Center Research	Canton44718	NCT06712316	Map
OH	The Christ Hospital Cancer Center	Cincinnati45219	NCT06712316	Map
OH	The Christ Hospital Cancer Center	Cincinnati45219	NCT06712355	Map
OH	University of Cincinnati Medical Center	Cincinnati45219	NCT06712316	Map
OH	Cleveland Clinic	Cleveland44195	NCT06618287	Map
OH	Cleveland Clinic	Cleveland44195-0001	NCT06712316	Map
OH	Cleveland Clinic Foundation	Cleveland44195-0001	NCT06712355	Map
OH	Cleveland Clinic Taussig Cancer Center	Cleveland44195	NCT07070232	Map
OH	The Cleveland Clinic Cancer Center at Fairview Hospital, Moll Pavilion	Cleveland44111	NCT06712355	Map
OH	The Cleveland Clinic Cancer Center At Fairview Hospital, Moll Pavilion	Cleveland44111	NCT06712316	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06712355	Map
OH	Kettering Medical Center	Kettering45429	NCT06712316	Map
OH	Kettering Medical Center	Kettering45429	NCT06712355	Map
OH	Cleveland Clinic - Hillcrest Hospital	Mayfield Heights44124	NCT06712316	Map
OH	Cleveland Clinic - Hillcrest Hospital	Mayfield Heights44124	NCT06712355	Map
OK	INTEGRIS Cancer Institute of Oklahoma	Oklahoma City73109	NCT06712316	Map
OR	Oncology Associates Of Oregon, Pc	Eugene97401	NCT07221149	Map
OR	Oncology Associates Of Oregon, Pc	Eugene97401	NCT07361497	Map
OR	Northwest Cancer Specialists, P.C.	Happy Valley97015	NCT07361497	Map
OR	Northwest Cancer Specialists, P.C.	Portland97213-2982	NCT07221149	Map
OR	Providence Portland Medical Center	Portland97213	NCT07291076	Map
OR	Providence St. Vincent Medical Center	Portland97225	NCT07291076	Map
OR	Oregon Oncology Specialists	Salem97301	NCT07173751	Map
PA	Lehigh Valley Health Network	Allentown18103	NCT07221357	Map
PA	St. Luke's Physician Group - St. Luke's Cancer Care Associates	Fountain Hill18015-1153	NCT06712355	Map
PA	University of Pittsburgh Medical Center	Pittsburgh15232	NCT07070232	Map
PA	WellSpan Oncology Research	York17403	NCT07361510	Map
SC	MUSC Hollings Cancer Center	Charleston29425	NCT07293351	Map
SC	Carolina Urologic Research Center, LLC	Myrtle Beach29572	NCT07293351	Map
SD	Sanford Cancer Center	Sioux Falls57104	NCT07221357	Map
TN	The West Clinic, P.C. dba West Cancer Center	Germantown38002	NCT07173751	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT06712316	Map
TN	University of Tennessee Medical Center	Knoxville37920	NCT06712355	Map
TN	Baptist Cancer Center	Memphis38120	NCT06712316	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07221149	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07221357	Map
TN	SCRI Oncology Partners	Nashville37203	NCT07361497	Map
TN	Tennessee Oncology	Nashville37203	NCT07291076	Map
TN	Vanderbilt University Medical Center	Nashville37232	NCT07291076	Map
TX	Texas Oncology - Amarillo Cancer Center	Amarillo79124	NCT07221149	Map
TX	Texas Oncology - Amarillo Cancer Center	Amarillo79124	NCT07361497	Map
TX	Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North	Arlington76012	NCT07221357	Map
TX	Texas Oncology-Austin Central	Austin78731	NCT07221149	Map
TX	Texas Oncology-Austin Central	Austin78731	NCT07361497	Map
TX	Texas Oncology, PA	Austin78705	NCT07221357	Map
TX	Texas Oncology	Beaumont77702	NCT07221149	Map
TX	Texas Oncology - Northeast Texas	Denison75020	NCT07221149	Map
TX	Texas Oncology	Denton76210	NCT07361497	Map
TX	Texas Oncology - DFW	Grapevine76051	NCT07221149	Map
TX	Kelsey-Seybold Clinic Main Campus	Houston77025	NCT07361510	Map
TX	Oncology Consultants PA	Houston77024	NCT07173751	Map
TX	Oncology Consultants PA	Houston77030	NCT07173751	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT06712355	Map
TX	The University of Texas MD Anderson Cancer Center	Houston77030	NCT07070232	Map
TX	NEXT Oncology - Irving	Irving75039	NCT06618287	Map
TX	South Texas Accelerated Research Therapeutics (START), LLC	San Antonio78229	NCT07070232	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT07221149	Map
TX	Texas Oncology - San Antonio	San Antonio78240	NCT07221357	Map
TX	Texas Oncology - San Antonio	San Antonio78217	NCT07361510	Map
TX	Texas Oncology - San Antonio Medical Center	San Antonio78229	NCT07361497	Map
TX	Texas Oncology Cancer Center	Sugar Land77479	NCT06712355	Map
TX	Texas Oncology - Northeast Texas	Tyler75702	NCT07361497	Map
UT	START Mountain Region	West Valley City84119	NCT07070232	Map
VA	Blue Ridge Cancer Care	Christiansburg24073	NCT07361497	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06712316	Map
VA	Virginia Cancer Specialists	Fairfax22031	NCT06712355	Map
VA	Hematology Oncology Associates of Fredericksburg, Inc.	Fredericksburg22408	NCT06712355	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT07221357	Map
VA	Virginia Oncology Associates	Norfolk23502	NCT07361497	Map
VA	VCU Massey Cancer Center	Richmond23298	NCT06712316	Map
VA	Virginia Commonwealth University School of Medicine	Richmond23298	NCT06712355	Map
VA	Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem	Salem24153	NCT07221149	Map
VA	Shenandoah Oncology	Winchester22601	NCT06712316	Map
VA	Shenandoah Oncology	Winchester22601	NCT06712355	Map
VA	Shenandoah Oncology, P.C.	Winchester22601	NCT07361510	Map
WA	Swedish Medical Center	Seattle98104	NCT06618287	Map
WA	Northwest Medical Specialties, PLLC	Tacoma98405	NCT07173751	Map
WA	Northwest Cancer Specialists, P.C.	Vancouver98684	NCT07221357	Map
WI	The Board of Regents of the University of Wisconsin	Madison53792-6188	NCT07070232	Map

Pumitamig clinical trials at a glance: phase × recruitment status

Phase	recruiting	not yet recruiting	Total
P1/P2	5	1	6
P2	3	1	4
P2/P3	3		3
P3	4		4

Recruiting Pumitamig clinical trials (17)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07221357	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	P2/P3	Untreated, Unresectable, or Metastatic Colorectal Cancer	990	Dec 2025
NCT07361497	NSCLCA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	P3	Non-small Cell Lung Cancer (NSCLC)	850	Mar 2026
NCT07221149	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)	P2/P3	Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	690	Mar 2026
NCT07492680	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	P2	Solid Tumors	260	Jul 2026
NCT07293351	RCCA Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)	P1/P2	Advanced Renal Cell Carcinoma (RCC)	254	Mar 2026
NCT07291076	HCCA Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)	P1/P2	Hepatocellular Carcinoma (HCC)	198	Mar 2026
NCT07361510	A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)	P3	Non-Small Cell Lung Cancer (NSCLC)	750	Mar 2026
NCT07579221	Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer	P1/P2	Non-Small Cell Lung Cancer	17	Nov 2026
NCT06618287	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors	P1/P2	Lung Cancer	416	Feb 2025
NCT07173751	ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer	P3	Breast Neoplasms	558	Oct 2025
NCT06712316	Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	P2/P3	Non-small Cell Lung Cancer	1,260	Jan 2025
NCT07070232	A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors	P1/P2	Advanced Solid Tumor	980	Aug 2025
NCT07297212	BNT327A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma	P2	Recurrent Glioblastoma	75	Jan 2026
NCT06712355	Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer	P3	Extensive-stage Small-cell Lung Cancer	621	Feb 2025
NCT06841055	BNT327Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment	P2	Non-small Cell Lung Cancer	60	Mar 2025
NCT07255404	A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer	P2	Pancreatic Ductal Adenocarcinoma (PDAC)	105	Dec 2025
NCT07147348	A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors	P1/P2	Advanced Solid Tumor	375	Aug 2025

Pumitamig clinical trials by indication

Advanced Solid Tumor (2)

NCT	Acronym	Phase	Status	Title
NCT07070232	—	P1/P2	recruiting	A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07147348	—	P1/P2	recruiting	A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Non-small Cell Lung Cancer (2)

NCT	Acronym	Phase	Status	Title
NCT06712316	—	P2/P3	recruiting	Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
NCT06841055	BNT327	P2	recruiting	Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Non-Small Cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07579221	—	P1/P2	not yet recruiting	Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Solid Tumors (1)

NCT	Acronym	Phase	Status	Title
NCT07492680	—	P2	not yet recruiting	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Advanced Renal Cell Carcinoma (RCC) (1)

NCT	Acronym	Phase	Status	Title
NCT07293351	RCC	P1/P2	recruiting	A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Hepatocellular Carcinoma (HCC) (1)

NCT	Acronym	Phase	Status	Title
NCT07291076	HCC	P1/P2	recruiting	A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

Non-small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT07361497	NSCLC	P3	recruiting	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (1)

NCT	Acronym	Phase	Status	Title
NCT07221149	—	P2/P3	recruiting	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Non-Small Cell Lung Cancer (NSCLC) (1)

NCT	Acronym	Phase	Status	Title
NCT07361510	—	P3	recruiting	A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Recurrent Glioblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT07297212	BNT327	P2	recruiting	A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Untreated, Unresectable, or Metastatic Colorectal Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT07221357	—	P2/P3	recruiting	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Pancreatic Ductal Adenocarcinoma (PDAC) (1)

NCT	Acronym	Phase	Status	Title
NCT07255404	—	P2	recruiting	A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer

Breast Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT07173751	—	P3	recruiting	ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06618287	—	P1/P2	recruiting	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Extensive-stage Small-cell Lung Cancer (1)

NCT	Acronym	Phase	Status	Title
NCT06712355	—	P3	recruiting	Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Pumitamig pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
NSCLC	NCT07361497	P3	recruiting	Non-small Cell Lung Cancer (NSCLC)	850	—
BNT327	NCT07297212	P2	recruiting	Recurrent Glioblastoma	75	—
BNT327	NCT06841055	P2	recruiting	Non-small Cell Lung Cancer	60	—

All Pumitamig trials (17)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07221357		A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer	P2/P3	recruiting	990	Bristol-Myers Squibb	Dec 2025
NCT07361497	NSCLC	A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)	P3	recruiting	850	Bristol-Myers Squibb	Mar 2026
NCT07221149		A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)	P2/P3	recruiting	690	Bristol-Myers Squibb	Mar 2026
NCT07492680		A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)	P2	not yet recruiting	260	Bristol-Myers Squibb	Jul 2026
NCT07293351	RCC	A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)	P1/P2	recruiting	254	Bristol-Myers Squibb	Mar 2026
NCT07291076	HCC	A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)	P1/P2	recruiting	198	Bristol-Myers Squibb	Mar 2026
NCT07361510		A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)	P3	recruiting	750	Bristol-Myers Squibb	Mar 2026
NCT07579221		Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer	P1/P2	not yet recruiting	17	M.D. Anderson Cancer Center	Nov 2026
NCT06618287		A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors	P1/P2	recruiting	416	Bristol-Myers Squibb	Feb 2025
NCT07173751		ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer	P3	recruiting	558	BioNTech SE	Oct 2025
NCT06712316		Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	P2/P3	recruiting	1,260	BioNTech SE	Jan 2025
NCT07070232		A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors	P1/P2	recruiting	980	BioNTech SE	Aug 2025
NCT07297212	BNT327	A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma	P2	recruiting	75	BioNTech SE	Jan 2026
NCT06712355		Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer	P3	recruiting	621	BioNTech SE	Feb 2025
NCT06841055	BNT327	Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment	P2	recruiting	60	BioNTech SE	Mar 2025
NCT07255404		A Clinical Trial Testing the Safety of BNT327 (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer	P2	recruiting	105	BioNTech SE	Dec 2025
NCT07147348		A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors	P1/P2	recruiting	375	BioNTech SE	Aug 2025

Pumitamig clinical trials: frequently asked questions

How many Pumitamig clinical trials are there?: 17 Pumitamig clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 15 are actively recruiting participants.
Are Pumitamig clinical trials recruiting in 2026?: Yes — 15 Pumitamig trials are actively recruiting in 2026, with 190 U.S. sites across 38 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Pumitamig being studied for?: Pumitamig is being studied for Advanced Solid Tumor, Non-small Cell Lung Cancer, Breast Neoplasms, Extensive-stage Small-cell Lung Cancer, Hepatocellular Carcinoma (HCC) and 11 more. The trials are grouped by indication on this page.
What phase is Pumitamig in?: Pumitamig clinical trials span 4 Phase 3, 4 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Pumitamig clinical trials?: The lead sponsor across the most Pumitamig trials is BioNTech SE, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pumitamigas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 16, 2026.

Related pages on Hipa.ai:

Pumitamig overview